This is a news story, published by Time Magazine, that relates primarily to Beckley Psytech news.
For more Beckley Psytech news, you can click here:
more Beckley Psytech newsFor more mental health treatments news, you can click here:
more mental health treatments newsFor more news from Time Magazine, you can click here:
more news from Time MagazineOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about
psychedelic drug development company Mindstate Design Labs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest psychedelic drug development news, Other psychedelics news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
psychedelics company MindMedTime Magazine
•
73% Informative
Psychedelics are thought to improve mental health by boosting neuroplasticity, helping the brain grow and form new connections.
The FDA said in June that it would not approve MDMA to treat PTSD without additional safety and efficacy data.
Some companies are trying to make psychedelics more palatable to regulators.
Researchers are working on a drug modeled off ibogaine that, at least in animal trials, seems able to mimic its impact on the brain with fewer unwanted side effects.
Beckley Psytech is developing a synthetic form of a drug similar to DMT, a compound in ayahuasca that results in short-lived but intense hallucinations.
Enveric Biosciences is preparing to begin human trials of a molecule that has structural similarities to psilocybin.
VR Score
64
Informative language
60
Neutral language
60
Article tone
semi-formal
Language
English
Language complexity
63
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
long-living
External references
13
Source diversity
12
Affiliate links
no affiliate links